A Phase 1b Open-label Study to Evaluate the Safety and Tolerability of MEDI4736 in Combination with Tremelimumab in Subjects with Advanced Non-small Cell Lung Cancer

The purpose of this study is to determine if MEDI4736 will be adequately tolerated in combination with tremelimumab in subjects with advanced non-small cell lung cancer (NSCLC).

Inclusion Criteria:

• Advanced non-small cell lung cancer

• Adequate organ and marrow function

Exclusion Criteria:

• Any concurrent chemotherapy, immunotherapy, biologic, or hormonal therapy for cancer treatment
Phase I
Rachel Sanborn, M.D.
MedImmune, LLC
Brenda Fisher
  • Oncology and Hematology Care Eastside